TICKERNERD
Menu
AIMAIMHealthcare · Biotechnology

AIM Stock Forecast: AIM ImmunoTech, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$0.22
+1.32% on the day

The 2 Wall Street analysts covering AIM ImmunoTech, Inc. hold a median 12-month price target of $4.25 — +1806.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 14 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$7.9M
Ticker Nerd rank
18 / 100
Median analyst target
$4.25
Analysts covering
2
Revenue$22K+37.5% y/y
Operating income−$2.2M
Net income−$3.0M
Free cash flow−$2.8M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.1%
1M
+1.3%
YTD
−79.7%
1Y
−91.2%
From 52W high
−92.0%
From 52W low
+1.3%
$0.22
$2.79
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AIM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores AIM ImmunoTech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
18 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
94
Revisions
67
Growth
55
Accruals
26
Momentum
24
Value
14
Quality
6
Volatility
5
Issuance
5

Size (94): Smaller than most of the companies we track.

Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AIM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AIM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Oct 25Jan 26Apr 26Jul 26AIMHigh $7.00Median $4.25Low $1.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $1.50Median $4.25High $7.00

The green dot is the last close — the median target sits +1806.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Aug 2026Ascendiant CapitalMaintainsBuy—
1 June 2026Ascendiant CapitalMaintainsBuy—
10 Apr 2026Ascendiant CapitalMaintainsBuy—
8 Dec 2025Ascendiant CapitalMaintainsBuy—
3 Oct 2025Ascendiant CapitalMaintainsBuy—
10 Dec 2024Ascendiant CapitalMaintainsBuy—
22 Oct 2024Maxim GroupMaintainsBuy—
3 Sept 2024Ascendiant CapitalMaintainsBuy—
10 Oct 2019Maxim GroupUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AIM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AIM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, AIM ImmunoTech, Inc. returned −91.2% against +17.0% for the S&P 500, dividends included.

AIM vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Oct 25Jan 26Apr 26Jul 26AIMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AIM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

AIM ImmunoTech, Inc. (AIM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.0×

Cheaper than 76% of US stocks

Price / sales
87.3×

Cheaper than 4% of US stocks

Price / book
0.8×

Cheaper than 78% of US stocks

EV / EBITDA
−0.1×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
4.0%

Higher than 36% of US stocks

Earnings growth (YoY)
37.5%

Higher than 70% of US stocks

Gross margin
81.8%

Higher than 92% of US stocks

Operating margin
−13511.5%

Higher than 2% of US stocks

Net margin
−45.5%

Higher than 11% of US stocks

Returns & dividend
Return on equity
−2382.3%

Higher than 1% of US stocks

Return on assets
−82.6%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

AIM ImmunoTech, Inc. (AIM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • AIM ImmunoTech, Inc. has a market value of $7.9M and an enterprise value of $706K.

  • Revenue in the twelve months to 31 Mar 2026: $94K. The latest quarter grew 4.0% year on year.

  • Net income over the same four quarters: −$13.3M, a −14123.4% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: −$11.7M.

  • Shares outstanding: 37.4M.

  • Trailing P/E: −0.0×; forward P/E: −0.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • AIM ImmunoTech, Inc. employs 19 people — $5K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

AIM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AIMAIM ImmunoTech, Inc.$7.9M
18
ENVBEnveric Biosciences, Inc.$6.6M
17
ERNAErnexa Therapeutics, Inc.$7.0M
37
CLGNCollPlant Biotechnologies Ltd.$6.6M
34
CURXCuranex Pharmaceuticals, Inc.$7.0M
6
KAPAKairos Pharma Ltd.$6.2M
40
CDIOCardio Diagnostics Holdings, Inc.$6.1M
20

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own AIM ImmunoTech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AIM news & analysis

AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video

GlobeNewsWire · 9 Sept 2026positive

AIM ImmunoTech released a CEO Corner video highlighting the scientific rationale, supportive data, and continued advancement of Ampligen in pancreatic cancer. The company is progressing its Phase 2 DURIPANC study and broader clinical strategy evaluating Ampligen's potential to reshape the tumor microenvironment and enhance checkpoint inhibition.

Why it matters — AIM watchers would care because this provides an update on the company's ongoing clinical progress with its lead drug candidate Ampligen in pancreatic cancer.

AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041

GlobeNewsWire · 2 Sept 2026positive

AIM ImmunoTech announced it has significantly expanded its Ampligen patent estate, securing long-duration intellectual property protection for the drug across major European markets and the United Kingdom through 2041, specifically covering Long COVID indications.

Why it matters — Extended patent protections through 2041 in Europe and the UK strengthen AIM's long-term exclusivity and commercial value for Ampligen in the Long COVID space.

AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039

GlobeNewsWire · 31 Aug 2026positive

AIM ImmunoTech announced that the U.S. Patent and Trademark Office has granted a patent covering the use of its drug Ampligen in combination with the PD-1 checkpoint inhibitor pembrolizumab for cancer treatment. The patent expands the company's oncology intellectual property protection for Ampligen through 2039.

Why it matters — AIM watchers would care because this broad U.S. patent strengthens and extends the company's intellectual property protection for Ampligen in oncology combinations through 2039.

AIM ImmunoTech Participates in the Virtual Investor ‘Why Now' On-Demand Conference

GlobeNewsWire · 27 Aug 2026neutral

AIM ImmunoTech participated in the Virtual Investor "Why Now" On-Demand Conference, with a video webcast of its presentation now available for viewing.

Why it matters — Investors and followers of AIM can access the company's on-demand presentation to hear its latest corporate update directly from management.

AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense' Article

GlobeNewsWire · 12 Aug 2026positive

AIM ImmunoTech CEO Thomas K. Equels authored an article in "Breaking Defense" calling for proactive evaluation of broad-spectrum antiviral countermeasures ahead of emerging viral threats, focusing on biodefense and military force protection. The piece highlights the potential role of such countermeasures in national defense planning.

Why it matters — AIM watchers would care because the CEO's publication in a defense-focused outlet raises the profile of the company's antiviral platform in the biodefense and military-protection space.

FAQ

Frequently asked questions about AIM stock

What is the AIM stock price forecast for 2026-2027?

The 2 Wall Street analysts covering AIM ImmunoTech, Inc. have a median 12-month price target of $4.25, with estimates ranging from $1.5 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AIM stock a buy right now?

Of the 2 analysts covering AIM ImmunoTech, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AIM ImmunoTech, Inc. 18 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AIM?

As at 14 Sept 2026, AIM ImmunoTech, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

Will AIM stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +1806.7% from the last close, and Ticker Nerd's factor model ranks AIM ImmunoTech, Inc. 18 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AIM stock forecast for 2030?

No analyst covering AIM ImmunoTech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AIM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.5 to $7 over the next 12 months.

How has AIM stock performed over the past year?

AIM ImmunoTech, Inc. returned -91.2% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AIM ImmunoTech, Inc. do?

AIM ImmunoTech Inc. is a biotechnology company focused on developing immuno-modulating therapeutics for cancer, viral diseases, and immune-related disorders.

What is the latest news on AIM?

The most recent item we track (GlobeNewsWire, 9 Sept 2026): "AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video". AIM ImmunoTech released a CEO Corner video highlighting the scientific rationale, supportive data, and continued advancement of Ampligen in pancreatic cancer. The company is progressing its Phase 2 DURIPANC study and broader clinical strategy evaluating Ampligen's potential to reshape the tumor microenvironment and enhance checkpoint inhibition.

Company

About AIM ImmunoTech, Inc.

AIM ImmunoTech Inc. is a biotechnology company focused on developing immuno-modulating therapeutics for cancer, viral diseases, and immune-related disorders. Its current portfolio centers on Ampligen, an investigational double-stranded RNA therapy being evaluated in clinical studies for oncology and selected viral and immune conditions, and Alferon N Injection, a natural-source interferon product used for specific approved indications. The company works across preclinical and clinical research, with an emphasis on immune system activation, antiviral defense, and combination approaches for difficult-to-treat diseases. AIM ImmunoTech serves the biopharmaceutical sector by advancing specialized therapies that target areas with limited treatment options, making it a recognized participant in immunotherapy and antiviral drug development.

CEO Mr. Thomas K. Equels Esq., J.D., M.S. · 19 employees · United States · https://aimimmuno.com